Medical cannabis is not a standard ADHD treatment in UK guidance. ADHD can be part of a private specialist assessment conversation, but the evidence for cannabis-based medicinal products in ADHD is limited, and the safety screening matters.
A diagnosis of ADHD does not automatically mean someone may qualify for a medical cannabis prescription. A prescriber would need to look at previous treatment history, current ADHD medicines, anxiety, sleep, substance-use risk, cardiovascular risk, mental-health history, impairment, driving, work responsibilities and whether a cannabis-based medicinal product is appropriate at all.
This guide is for UK patients and carers preparing for a realistic conversation. It is not medical advice, it is not a recommendation to use cannabis for ADHD, and it does not replace an ADHD clinician, GP, pharmacist, psychiatrist or specialist prescriber. For general access context, see MCPH’s medical cannabis qualifying conditions guide and how the UK medical cannabis prescription process works.
The short answer
NICE ADHD guidance focuses on recognised ADHD care, including environmental changes, psychological support where appropriate, and ADHD medicines started by healthcare professionals with training and expertise in ADHD. NICE cannabis-based medicinal products guidance does not recommend medical cannabis for ADHD.
That means a patient should be wary of confident claims that cannabis treats ADHD symptoms. Some people with ADHD report using cannabis or feeling that it affects sleep, restlessness or emotional intensity. That is not the same as strong clinical evidence that prescribed medical cannabis improves core ADHD symptoms.
The safer question is whether a specialist thinks a cannabis-based medicine is suitable for this individual patient after a proper assessment. The answer may be no.
Why ADHD needs careful screening
ADHD rarely arrives as a tidy, isolated label. Many people also have anxiety, depression, trauma history, sleep problems, autism, tics, substance-use concerns, pain, appetite issues, or difficulties with emotional regulation. Some people are taking stimulant medicines. Others use atomoxetine, guanfacine, antidepressants, sleeping tablets, pain medicines, over-the-counter CBD, alcohol, or non-prescribed cannabis.
That wider picture matters because THC and CBD can affect mood, sleep, concentration, alertness, anxiety and how other medicines work. The prescriber needs to understand whether cannabis could worsen the exact problems the patient is trying to manage.
Screening should include:
- current ADHD symptoms and impairment
- previous ADHD treatments and why they helped, failed, caused problems or were unsuitable
- stimulant and non-stimulant medicines
- anxiety, depression, suicidality, psychosis, bipolar or mania history
- sleep problems and daytime sedation risk
- alcohol, substance-use concerns and non-prescribed cannabis use
- cardiovascular history, palpitations, blood pressure issues or fainting
- driving, work, study, caring and safety-sensitive responsibilities
Being honest about self-medication matters. It should not be treated as a moral confession, but hiding it can make the risk assessment less safe.
Previous treatment history and records
In private medical cannabis access, clinics commonly look for previous relevant treatment history. MCPH often frames this as at least two relevant treatments where applicable, but it is not a tick-box decision and it is not the whole decision.
For ADHD, previous treatment history may include ADHD medication trials, psychological or coaching support, environmental adjustments, sleep work, treatment for anxiety or depression, or other clinically relevant care. The clinician decides what matters for the individual case.
The Summary Care Record from the GP surgery is often the practical place to start. It may show current medicines, recent medicines, coded diagnoses and allergies. If the SCR does not show the ADHD history clearly, a clinic may ask for diagnostic letters, shared-care documents, psychiatry notes or clinic letters.
This is a records step, not an instruction to convince a GP to prescribe medical cannabis.
ADHD medicines and interaction checks
People with ADHD may be taking methylphenidate, lisdexamfetamine, dexamfetamine, atomoxetine, guanfacine or other medicines. Some are also taking antidepressants, sleep medicines, pain medicines or supplements.
NHS medical cannabis guidance says CBD and THC can affect how other medicines work. NICE ADHD guidance also treats ADHD medication as specialist-led, with monitoring and individualised prescribing. That means a cannabis-based medicinal product should not be added casually around stimulant or non-stimulant medicines.
The article cannot act as an interaction checker. The useful patient action is to give the prescriber and pharmacist a complete list:
- prescribed medicines
- over-the-counter medicines
- supplements
- CBD products
- alcohol intake
- non-prescribed cannabis or other substances
- previous bad reactions to stimulants, sedatives or cannabis
The clinician can then assess whether interactions, blood pressure, heart rate, sleep, anxiety, alertness, appetite or mood need closer review.
Anxiety, sleep and mental-health risk
Some ADHD patients research medical cannabis because sleep is poor, anxiety is high, or stimulants feel difficult. Those are real patient concerns, but they need careful separation.
If the main issue is anxiety, panic, low mood, trauma symptoms, mania, psychosis, suicidal thoughts, heavy substance use or worsening sleep, the clinician may need to address that directly rather than treating ADHD as the only problem. THC-containing products can cause or worsen anxiety, panic, paranoia, impaired concentration, sleepiness or perceptual changes in some people.
Medical cannabis should not be framed as a way to avoid ADHD care, skip mental-health treatment, or balance out stimulant side effects without review. If current ADHD medicine is causing problems, that should be discussed with the ADHD prescriber or relevant clinician.
Do not stop, swap or add prescribed ADHD or mental-health medicines without clinical advice.
What a careful assessment may ask
A specialist may ask:
- When were you diagnosed with ADHD, and by whom?
- What symptoms affect your daily life now?
- Which treatments have you tried, and what happened?
- Are you taking stimulants, atomoxetine, guanfacine or other medicines?
- Do you have anxiety, depression, bipolar disorder, psychosis history or suicidal thoughts?
- How is your sleep, appetite and concentration?
- Do you currently use cannabis, CBD, alcohol or other substances?
- Do you drive or work in a safety-sensitive role?
- What outcome are you hoping for, and how would it be monitored?
Patients can ask about forms such as oil, flower or extracts if that is part of the consultation, but product choice, route, dose and monitoring sit with the prescriber.
Questions to ask a clinic
Useful questions include:
- What evidence do you use when assessing ADHD and medical cannabis?
- Why might ADHD be suitable or unsuitable in my case?
- How would my stimulant or non-stimulant medicines affect the decision?
- Are anxiety, sleep, substance use or mental-health risks a concern?
- What records do you need from my GP surgery or ADHD service?
- How would you monitor attention, mood, sleep, impairment and side effects?
- What would make you pause, reduce risk or decide not to prescribe?
- How do driving, study, work or caring responsibilities affect suitability?
The point is not to persuade the clinician. It is to make sure the assessment is honest, clinically grounded and useful.
What this article is not saying
This article is not saying medical cannabis treats ADHD. It is not saying ADHD automatically makes someone eligible. It is not recommending CBD, THC, flower, oil, extracts, a clinic, a pharmacy or a dose.
It is saying that ADHD can be part of a specialist assessment conversation for some UK patients, but the evidence is limited and the screening has to be careful. Previous treatment history, current ADHD medicines, mental-health risk, substance-use history, sleep, impairment and interactions all matter.
Sources
- NHS: Medical cannabis
- NHS: Attention deficit hyperactivity disorder (ADHD)
- NICE: ADHD: diagnosis and management, NG87
- NICE: Cannabis-based medicinal products, NG144
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- RCPsych: Cannabis and mental health
